Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: A prospective, randomized, double-blind, dose-ranging study

Clinical and Experimental Dermatology

Volumn 37, Issue 7, 2012, Pages 729-734

  Dogra, Sunil ^a   Krishna, V ^a   Kanwar, A J ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; PLACEBO;

ADULT; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAIR LOSS; HEADACHE; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYALGIA; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PARALLEL DESIGN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMIC THERAPY; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; YOUNG ADULT;

EID: 84866733744     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2012.04440.x     Document Type: Article

References (28)

1. Nestle FO, Kaplan DH, Barker J,. Psoriasis. N Engl J Med 2009; 361: 496-509.
2. Jankovic S, Raznatovic M, Marinkovic J, et al. Health-related quality of life in patients with psoriasis. J Cutan Med Surg 2011; 15: 29-36.
3. Kanwar AJ, Yadav S, Dogra S,. Psoriasis: what is new in nonbiologic systemic therapy in the era of biologics? Indian J Dermatol Venereol Leprol 2010; 76: 622-33.
4. Warren RB, Chalmers RJ, Griffiths CE, Menter A,. Methotrexate for psoriasis in the era of biological therapy. Clin Exp Dermatol 2008; 33: 551-4.
5. Kalb RE, Strober B, Weinstein G, Lebwohl M,. Methotrexate and psoriasis. National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009; 60: 824-37.
6. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011; 65: 137-74.
7. Boffa MJ, Chalmers RJG,. Methotrexate for psoriasis. Clin Exp Dermatol 1996; 21: 399-408.
8. Puzenat E, Bronsard V, Prey S, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 2): 10-16.
9. Haustein U-F, Rytter M,. Methotrexate in psoriasis: 26 years' experience of low-dose long-term treatment. J Eur Acad Dermatol Venereol 2000; 14: 382-8.
10. Dooren-Grebe Van RJ, Kuijpers ALA, Mulder J, et al. Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 1994; 130: 204-10.
11. Collins P, Rogers S,. The efficacy of methotrexate in psoriasis- a review of 40 cases. Clin Exp Dermatol 1992; 17: 257-60.
12. Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate- to-severe chronic plaque psoriasis. N Engl J Med 2003; 349: 658-65.
13. Batchelor JM, Ingram JR, Williams H,. Adalimumab vs methotrexate for the treatment of chronic plaque psoriasis. Arch Dermatol 2009; 145: 704-6.
14. Kumar B, Saraswat A, Kaur I,. Short-term methotrexate therapy in psoriasis: a study of 197 patients. Int J Dermatol 2002; 41: 444-8.
15. Furst DE, Koehnke R, Burmeister LF, et al. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol 1989; 16: 313-20.
16. Schnabel A, Reinhold-Keller E, Willmann V, et al. Tolerabilty of methotrexate starting with 15 or 25 mg/week for rheumatoid arthritis. Rheumatol Int 1994; 14: 33-8.
17. Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assissted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66: 1443-9.
18. Kaur I, Dogra S, De D, et al. Systemic methotrexate treatment in childhood psoriasis: further experience in 24 children from India. Pediatr Dermatl 2008; 25: 184-8.
19. Said S, Jeffes EW, Weinstein GD,. Methotrexate. Clin Dermatol 1997; 15: 781-97.
20. Bannwarth B, Labart L, Moride Y, et al. Methotrexate in rheumatoid arthritis. An update. Drugs 1994; 47: 25-50.
21. Roenigk HH, Maibach HI,. Methotrexate. In: Psoriasis (, Roenigk HH, Maibach HI, eds). New York, NY: Marcel Dekker, Inc, 1992: pp 609-29.
22. Mittal R, Malhotra S, Pandhi P, et al. Efficacy and safety of combination acitretin and pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial. Arch Dermatol 2009; 145: 387-93.
23. Rau R,. Treatment with low-dose methotrexate in chronic polyarthritis. Rev Literature Z Rheumatol Dec 1986; 45: 283-95.
24. Yang CP, Kuo MC, Guh JY, et al. Pancytopenia after low dose methotrexate therapy in a hemodialysis patient: case report and review of literature. Ren Fail 2006; 28: 95-7.
25. Jih DM, Werth VP,. Thrombocytopenia after a single test dose of methotrexate. J Am Acad Dermatol 1998; 39: 349-51.
26. Cohen PR, Schulze KE, Nelson BR,. Pancytopenia after single intradermal infiltration of methotrexate. J Drugs Dermatol 2005; 4: 648-52.
27. Singh YP, Aggarwal A, Misra R, et al. Low-dose methotrexate induced pancytopenia. Clin Rheumatol 2007; 26: 84-7.
28. Shen S, O'Brien T, Yap LM, et al. The use of methotrexate in dermatology: a review. Australas J Dermatol 2012; 53: 1-18.